Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis
出版年份 2021 全文链接
标题
Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-10-16
DOI
10.3389/fphar.2021.759249
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
- (2020) Sho Suzuki et al. GUT
- The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori
- (2020) Seung Woo Lee et al. MEDICINE
- Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy
- (2020) Mitsushige Sugimoto et al. Antibiotics-Basel
- Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
- (2019) Mitsushige Sugimoto et al. Frontiers in Pharmacology
- Personalized therapy for Helicobacter pylori : CYP2C19 genotype effect on first-line triple therapy
- (2019) Azucena Arévalo Galvis et al. HELICOBACTER
- Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition
- (2019) Mototsugu Kato et al. HELICOBACTER
- Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy
- (2018) Haruhiko Ozaki et al. DIGESTION
- Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens
- (2017) Tadashi Shimoyama et al. INTERNAL MEDICINE
- Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
- (2016) T. Kagami et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study
- (2016) Kittichet Phiphatpatthamaamphan et al. Asian Pacific Journal of Cancer Prevention
- Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report
- (2016) P Malfertheiner et al. GUT
- Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis
- (2016) Hitomi Ichikawa et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection
- (2015) Jyh-Chin Yang et al. Clinical Gastroenterology and Hepatology
- Sequential therapy for 10 days versus triple therapy for 14 days in the eradication ofHelicobacter pyloriin the community and hospital populations: a randomised trial
- (2015) Jyh-Ming Liou et al. GUT
- Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole
- (2014) S. Sahara et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of TailoredHelicobacter pyloriEradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion
- (2014) Mitsushige Sugimoto et al. HELICOBACTER
- Improved Efficacy of Proton Pump Inhibitor - Amoxicillin - Clarithromycin Triple Therapy forHelicobacter pyloriEradication in Low Clarithromycin Resistance Areas or for Tailored Therapy
- (2013) Sanchai Prasertpetmanee et al. HELICOBACTER
- Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials
- (2013) Hui-Lin Tang et al. PLoS One
- Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype
- (2012) M. Sugimoto et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Association of Helicobacter pylori dupA With the Failure of Primary Eradication
- (2012) Seiji Shiota et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole
- (2010) Jeong Hoon Lee et al. Gut and Liver
- The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people
- (2010) L. Zhang et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy
- (2009) Mitsushige Sugimoto et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects
- (2009) Chise Kodaira et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism
- (2008) Horng-Yuan Lou et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Tailored eradication therapy based on fecalHelicobacter pyloriclarithromycin sensitivities
- (2008) Takashi Kawai et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started